Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China

Stock News

Sep 09

Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.

The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.

Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1155717358"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155717358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155717358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155717358","market":"fut","top_or_hot":-1,"title":"Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China","media":"Stock News","content":"<p><b>Apeloa Pharmaceutical Co.,Ltd.</b> (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.<br><br>The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.<br><br>Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-09 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Apeloa Pharmaceutical Co.,Ltd.</b> (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.<br><br>The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.<br><br>Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1155717358","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155717358","pubTimestamp":1788947414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0060":"抗癌","IPOS":"Renaissance International IPO ETF","BK0188":"融资融券","BK0239":"医药制造","000739":"普洛药业"},"translate_title":"Apeloa Pharmaceutical 在中国获得头孢地妥仑吡沃酯原料药的监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"000739":1},"content_text":"Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}